Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.

Rapid Review

Pharmacoeconomic Evaluation

Summary

Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.